MedTrace Logo

Thrombolysis of Urokinase for Minor Stroke

NCT04420351 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1005

Last updated 2023-11-14

No results posted yet for this study

Summary

This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of Urokinase Thrombolysis for patients with minor stroke.

Conditions

  • Minor Stroke

Interventions

DRUG

Urokinase thrombolysis

The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.

DRUG

Aspirin;Clopidogrel

The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Shanghai 10th People's Hospital

    collaborator OTHER

  • General Hospital of Shenyang Military Region

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Principal Investigators

  • Bo Song, MD;PhD · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-04
Primary Completion
2023-02-18
Completion
2023-02-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420351 on ClinicalTrials.gov